SMP201100010B - Composizioni e metodi di uso di anticorpi terapeutici - Google Patents

Composizioni e metodi di uso di anticorpi terapeutici

Info

Publication number: SMP201100010B
Authority: SM; San Marino
Prior art keywords: compositions; methods; antibodies; therapeutic antibodies; baffr
Prior art date: 2008-07-17

Application number

SM201100010T

Other languages

English (en)

Other versions

SMAP201100010A (it

Inventor

Christoph Heusser

Julia Neugebauer

Eveline Schaadt

Stefanie Urlinger

Maximilian Woisetschlaeger

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-17

Filing date

2011-02-17

Publication date

2011-09-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP201100010(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-17 Application filed by Novartis Ag filed Critical Novartis Ag

2011-05-06 Publication of SMAP201100010A publication Critical patent/SMAP201100010A/it

2011-09-09 Publication of SMP201100010B publication Critical patent/SMP201100010B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SM201100010T 2008-07-17 2011-02-17 Composizioni e metodi di uso di anticorpi terapeutici SMP201100010B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08160671		2008-07-17
EP09160326		2009-05-15
PCT/EP2009/059030 WO2010007082A1 (en)	2008-07-17	2009-07-15	Compositions and methods of use for therapeutic antibodies

Publications (2)

Publication Number	Publication Date
SMAP201100010A SMAP201100010A (it)	2011-05-06
SMP201100010B true SMP201100010B (it)	2011-09-09

Family

ID=41073830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201100010T SMP201100010B (it)	2008-07-17	2011-02-17	Composizioni e metodi di uso di anticorpi terapeutici

Country Status (40)

Country	Link
US (3)	US8106163B2 (it)
EP (1)	EP2315780B8 (it)
JP (2)	JP5767109B2 (it)
KR (2)	KR101314369B1 (it)
CN (1)	CN102119174B (it)
AR (1)	AR072749A1 (it)
AU (1)	AU2009272771B2 (it)
BR (1)	BRPI0915928B8 (it)
CA (1)	CA2730063C (it)
CL (1)	CL2011000086A1 (it)
CR (1)	CR11863A (it)
CU (1)	CU23878B1 (it)
CY (1)	CY1116800T1 (it)
DK (1)	DK2315780T3 (it)
DO (1)	DOP2011000016A (it)
EA (1)	EA024492B1 (it)
EC (1)	ECSP11010761A (it)
ES (1)	ES2547270T3 (it)
GE (1)	GEP20146129B (it)
HR (1)	HRP20151227T1 (it)
HU (1)	HUE025778T2 (it)
IL (1)	IL210485A (it)
JO (1)	JO3149B1 (it)
MA (1)	MA32481B1 (it)
MX (1)	MX2011000616A (it)
MY (1)	MY158980A (it)
NI (1)	NI201100017A (it)
NZ (1)	NZ590057A (it)
PE (1)	PE20110563A1 (it)
PL (1)	PL2315780T3 (it)
PT (1)	PT2315780E (it)
RS (1)	RS54299B1 (it)
SG (1)	SG193805A1 (it)
SI (1)	SI2315780T1 (it)
SM (1)	SMP201100010B (it)
SV (1)	SV2011003807A (it)
TW (1)	TWI508742B (it)
UY (1)	UY31987A (it)
WO (1)	WO2010007082A1 (it)
ZA (1)	ZA201008952B (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) *	2007-08-10	2009-07-09	Protelix, Inc.	Universal fibronectin type III binding-domain libraries
US8680019B2 (en) *	2007-08-10	2014-03-25	Protelica, Inc.	Universal fibronectin Type III binding-domain libraries
US9458240B2 (en) *	2010-12-10	2016-10-04	Novartis Pharma Ag	Anti-BAFFR antibody formulations
JP2012153788A (ja) *	2011-01-25	2012-08-16	Nitto Denko Corp	光学用粘着シート
NZ724296A (en) *	2011-05-13	2020-05-29	Ganymed Pharmaceuticals Ag	Antibodies for treatment of cancer expressing claudin 6
US9216219B2 (en) *	2012-06-12	2015-12-22	Novartis Ag	Anti-BAFFR antibody formulation
US10435474B2 (en)	2013-12-24	2019-10-08	Ossianix, Inc.	Baff selective binding compounds and related methods
AU2015315834B2 (en)	2014-01-31	2019-12-12	Boehringer Ingelheim International Gmbh	Novel anti-BAFF antibodies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en)	2014-10-14	2018-06-05	Novartis Ag	Antibody molecules to PD-L1 and uses thereof
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3316902A1 (en)	2015-07-29	2018-05-09	Novartis AG	Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt)	2015-07-29	2021-07-26	Novartis Ag	Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
AU2016369537B2 (en)	2015-12-17	2024-03-14	Novartis Ag	Antibody molecules to PD-1 and uses thereof
KR20180108651A (ko)	2016-02-10	2018-10-04	노파르티스 아게	일차 쇼그렌 증후군의 치료를 위한 pi3k의 활성 또는 기능의 억제제의 용도
CN116041514A (zh) *	2016-06-06	2023-05-02	希望之城	Baff-r抗体及其用途
US11197928B2 (en)	2017-01-13	2021-12-14	Board Of Regents, The University Of Texas System	Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
IL309444A (en) *	2017-05-24	2024-02-01	Als Therapy Development Inst	Therapeutic anti-cd40 ligand antibodies
IL271194B2 (en) *	2017-06-20	2024-10-01	Teneobio Inc	Anti-bcma heavy chain-only antibodies
MX2021000708A (es) *	2018-07-20	2021-03-25	Teneobio Inc	Anticuerpos de cadena pesada que se unen al cd19.
TWI859192B (zh) *	2019-03-29	2024-10-21	日商中外製藥股份有限公司	包含抗il-6受體抗體之bbb功能低下之抑制劑
CR20210576A (es)	2019-05-21	2021-12-15	Novartis Ag	Moléculas de unión a cd19 y usos de las mismas
KR20220093347A (ko) *	2019-11-06	2022-07-05	노파르티스 아게	쇼그렌 증후군의 치료
CN112813099A (zh) *	2019-11-15	2021-05-18	上海细胞治疗集团有限公司	一种在活化的t细胞中具有高活性的启动子
CN116133687A (zh)	2020-08-04	2023-05-16	诺华股份有限公司	B细胞恶性肿瘤的治疗
TW202206103A (zh)	2020-08-04	2022-02-16	瑞士商諾華公司	Ｃｌｌ的治療
CN118459585A (zh) *	2020-09-07	2024-08-09	白先宏	Baff-r结合分子及其应用
US20250215081A1 (en)	2020-11-06	2025-07-03	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) *	2021-03-15	2024-02-20	盛禾(中国)生物制药有限公司	一种抗baffr抗体及其应用
JP2024516019A (ja)	2021-05-04	2024-04-11	ノバルティスアーゲー	抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
IL308045A (en)	2021-05-04	2023-12-01	Novartis Ag	Treatment of lupus nephritis using antibuffer antibodies
TW202440636A (zh)	2023-03-21	2024-10-16	美商傳記５５有限公司	Ｃｄ１９／ｃｄ３８多特異性抗體
WO2025058962A1 (en) *	2023-09-11	2025-03-20	Absci Corporation	High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en)	2023-12-19	2025-06-26	Basf Se	Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS51157B (sr) *	1999-08-17	2010-10-31	Biogen Idec Ma Inc.	Baff receptor (bcma), imunoregulatorni agens
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
KR20070107687A (ko) *	2004-12-31	2007-11-07	제넨테크, 인크.	Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US20100166741A1 (en) *	2006-07-13	2010-07-01	Genentech , Inc.	Altered br-3 binding polypeptides

2009
- 2009-07-15 KR KR1020117001052A patent/KR101314369B1/ko active Active
- 2009-07-15 MX MX2011000616A patent/MX2011000616A/es active IP Right Grant
- 2009-07-15 MY MYPI2010005960A patent/MY158980A/en unknown
- 2009-07-15 HU HUE09797499A patent/HUE025778T2/en unknown
- 2009-07-15 CN CN200980127408.2A patent/CN102119174B/zh active Active
- 2009-07-15 DK DK09797499.2T patent/DK2315780T3/en active
- 2009-07-15 PE PE2011000038A patent/PE20110563A1/es active IP Right Grant
- 2009-07-15 EA EA201100191A patent/EA024492B1/ru not_active IP Right Cessation
- 2009-07-15 AU AU2009272771A patent/AU2009272771B2/en active Active
- 2009-07-15 SI SI200931293T patent/SI2315780T1/sl unknown
- 2009-07-15 US US12/503,175 patent/US8106163B2/en active Active
- 2009-07-15 RS RS20150667A patent/RS54299B1/en unknown
- 2009-07-15 WO PCT/EP2009/059030 patent/WO2010007082A1/en active Application Filing
- 2009-07-15 BR BRPI0915928A patent/BRPI0915928B8/pt active IP Right Grant
- 2009-07-15 KR KR1020137019574A patent/KR101545795B1/ko active Active
- 2009-07-15 PL PL09797499T patent/PL2315780T3/pl unknown
- 2009-07-15 ES ES09797499.2T patent/ES2547270T3/es active Active
- 2009-07-15 PT PT97974992T patent/PT2315780E/pt unknown
- 2009-07-15 GE GEAP200912063A patent/GEP20146129B/en unknown
- 2009-07-15 SG SG2013062567A patent/SG193805A1/en unknown
- 2009-07-15 EP EP09797499.2A patent/EP2315780B8/en active Active
- 2009-07-15 UY UY0001031987A patent/UY31987A/es active IP Right Grant
- 2009-07-15 CA CA2730063A patent/CA2730063C/en active Active
- 2009-07-15 AR ARP090102678A patent/AR072749A1/es active IP Right Grant
- 2009-07-15 NZ NZ590057A patent/NZ590057A/xx unknown
- 2009-07-15 JP JP2011517915A patent/JP5767109B2/ja active Active
- 2009-07-15 HR HRP20151227TT patent/HRP20151227T1/hr unknown
- 2009-07-16 TW TW098124126A patent/TWI508742B/zh active
- 2009-07-16 JO JOP/2009/0267A patent/JO3149B1/ar active
2010
- 2010-12-13 ZA ZA2010/08952A patent/ZA201008952B/en unknown
- 2010-12-21 CR CR11863A patent/CR11863A/es unknown
2011
- 2011-01-06 IL IL210485A patent/IL210485A/en active IP Right Grant
- 2011-01-14 DO DO2011000016A patent/DOP2011000016A/es unknown
- 2011-01-14 MA MA33525A patent/MA32481B1/fr unknown
- 2011-01-14 NI NI201100017A patent/NI201100017A/es unknown
- 2011-01-14 CL CL2011000086A patent/CL2011000086A1/es unknown
- 2011-01-17 CU CUP2011000013A patent/CU23878B1/es active IP Right Grant
- 2011-01-17 SV SV2011003807A patent/SV2011003807A/es unknown
- 2011-01-17 EC EC2011010761A patent/ECSP11010761A/es unknown
- 2011-02-17 SM SM201100010T patent/SMP201100010B/it unknown
- 2011-12-15 US US13/326,569 patent/US9382326B2/en active Active
- 2011-12-15 US US13/326,514 patent/US9340620B2/en active Active
2015
- 2015-04-10 JP JP2015081099A patent/JP6077587B2/ja active Active
- 2015-10-19 CY CY20151100934T patent/CY1116800T1/el unknown

Also Published As

Publication number	Publication date
MX2011000616A (es)	2011-02-24
NI201100017A (es)	2012-08-17
JP5767109B2 (ja)	2015-08-19
SMAP201100010A (it)	2011-05-06
US20120183529A1 (en)	2012-07-19
RS54299B1 (en)	2016-02-29
HUE025778T2 (en)	2016-05-30
PL2315780T3 (pl)	2016-01-29
EP2315780B1 (en)	2015-08-19
TW201006493A (en)	2010-02-16
CA2730063C (en)	2017-04-18
CA2730063A1 (en)	2010-01-21
BRPI0915928A2 (pt)	2015-11-03
SI2315780T1 (sl)	2015-11-30
US20100021452A1 (en)	2010-01-28
EA201100191A1 (ru)	2011-08-30
US9340620B2 (en)	2016-05-17
BRPI0915928B8 (pt)	2021-05-25
US9382326B2 (en)	2016-07-05
ECSP11010761A (es)	2011-02-28
CY1116800T1 (el)	2017-03-15
MY158980A (en)	2016-11-30
AU2009272771B2 (en)	2012-09-20
MA32481B1 (fr)	2011-07-03
IL210485A (en)	2015-03-31
CN102119174A (zh)	2011-07-06
GEP20146129B (en)	2014-08-11
EP2315780A1 (en)	2011-05-04
SV2011003807A (es)	2011-03-23
WO2010007082A1 (en)	2010-01-21
PE20110563A1 (es)	2011-08-29
DK2315780T3 (en)	2015-10-19
US8106163B2 (en)	2012-01-31
JO3149B1 (ar)	2017-09-20
KR101314369B1 (ko)	2013-10-10
JP2015133983A (ja)	2015-07-27
UY31987A (es)	2010-02-26
DOP2011000016A (es)	2011-02-15
ZA201008952B (en)	2012-01-25
JP2011527896A (ja)	2011-11-10
PT2315780E (pt)	2015-11-30
KR20110020914A (ko)	2011-03-03
EP2315780B8 (en)	2015-09-23
ES2547270T3 (es)	2015-10-05
NZ590057A (en)	2012-08-31
JP6077587B2 (ja)	2017-02-08
AU2009272771A1 (en)	2010-01-21
CL2011000086A1 (es)	2011-07-01
CR11863A (es)	2011-02-11
HRP20151227T1 (hr)	2015-12-18
US20120195913A1 (en)	2012-08-02
AR072749A1 (es)	2010-09-15
KR20130098432A (ko)	2013-09-04
CN102119174B (zh)	2015-01-21
SG193805A1 (en)	2013-10-30
TWI508742B (zh)	2015-11-21
KR101545795B1 (ko)	2015-08-19
BRPI0915928B1 (pt)	2020-10-20
IL210485A0 (en)	2011-03-31
EA024492B1 (ru)	2016-09-30
HK1150839A1 (en)	2012-01-13
CU23878B1 (es)	2013-04-19
CU20110013A7 (es)	2012-06-21

Publication	Publication Date	Title
SMAP201100010A (it)	2011-05-06	Composizioni e metodi di uso di anticorpi terapeutici.
EP2322557A3 (en)	2011-08-03	Compositions and methods for treating proliferative disorders
EA201100524A1 (ru)	2011-10-31	Азаиндазолы в качестве антагонистов рецептора ccr1
MX380755B (es)	2025-03-12	Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA201270467A1 (ru)	2012-09-28	Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
GB0906579D0 (en)	2009-05-20	Pharmaceuticals, compositions and methods of making and using the same
PH12015500276A1 (en)	2015-04-27	Treatment of immune-related and inflammatory diseases
EA200970765A1 (ru)	2009-12-30	2-аминопиримидиновые модуляторы рецептора hгистамина
EA201390821A1 (ru)	2013-10-30	Антагонисты рецепторов лизофосфатидной кислоты и их применение
MY163055A (en)	2017-08-15	Polycyclic antagonists of lysophosphatidic acid receptors
PH12013501837A1 (en)	2013-11-18	Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
EA200970113A1 (ru)	2009-06-30	Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
EA201101009A1 (ru)	2012-01-30	АНТАГОНИСТЫ C5aR
EA200602243A1 (ru)	2007-04-27	3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MX2011011338A (es)	2012-04-19	Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
IN2012DN06588A (it)	2015-10-23
EA201290759A1 (ru)	2013-03-29	Антитела
WO2010120518A3 (en)	2011-03-10	Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein
EA201190209A1 (ru)	2012-04-30	Соединения для лечения метаболических расстройств
WO2011047058A3 (en)	2011-09-09	Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EA201190208A1 (ru)	2012-04-30	Соединения для лечения метаболических расстройств
CO6341571A2 (es)	2011-11-21	Composiciones y metodos de uso para anticuerpos terapeuticos
TN2010000599A1 (en)	2012-05-24	Compositions and methods of use for therapeutic antiodies